Skip to Content

Posts tagged with "Business and Markets"

  • Business and Markets

    Twenty-One Billion Dollars. Really.

    Ibrutinib seems to be worth even more than everyone thought! As of this morning, AbbVie has won what was apparently a lively bidding war for Pharmacyclics, paying $21 billion for the company. Now that is a lot of money, and I’m not sure that I can made those numbers add up, but presumably there are… Read More
  • Business and Markets

    AZ Spins Off Anti-Infectives

    Word came yesterday that AstraZeneca is spinning off its anti-infectives division into a separate subsidiary company. This does not appear to have been their first choice – they’ve been shopping these assets around for actual cash, but had no takers (at least, on their terms). Here’s what they’re telling the employees: . . . Read More
  • Business and Markets

    All That Cash

    From the LifeSciVC blog, here’s a revealing comparison of the amount of money going into startups in this business. This is why I tend to get worked up about the number of stock buyback plans among the big pharma players. It would seem that there is so much cash sloshing around on the balance sheets… Read More
  • Business and Markets

    Cutbacks at Merck Serono

    Merck/Serono (Merck KGaA of Darmstadt) is apparently cutting back in Billerica, their US research site. According to FierceBiotech, though, they’re not saying by how much: “a limited number of discovery positions have been impacted in our research organization. We are working to re-assign as many of those positions as possible in the or… Read More
  • Business and Markets

    Bonne Chance, Brandicourt

    Sanofi’s CEO hunt has ended, and the roue de la fortune has pointed to Bayer’s Olivier Brandicourt. (I’m tempted to keep dropping French phrases every couple of lines, but I figure that no one will stand for it, so you can work them in mentally as appropriate). But before his two years at Bayer, Brandicourt… Read More
  • Business and Markets

    Layoffs at Boehringer Ingelheim

    According to FierceBiotech, Boehinger is cutting staff in Ridgefield, CT. They are, they say, “in the process of rebalancing its workforce in the U.S. to put the company in the best position for future growth”. You won’t find many sentences that says “layoffs” more than that one. I haven’t heard from any of my ch… Read More
  • Business and Markets

    AstraZeneca’s Anti-Infective Woes

    According to Fierce Pharma, AstraZeneca is having trouble unloading its anti-infectives division. Part of the problem seems to be that they’re trying to spin out the whole package at once: The pharma giant also specifically sought out venture groups that had been investing in anti-infectives in an effort to find a buyer for the Waltham… Read More
  • Business and Markets

    A Trick Question

    I got a kick out of this FierceBiotech story on Pfizer and Ian Read, based on this talk with him. Pfizer probably won’t be building up the innovative side of the business by scooping up a bunch of biotechs. “[I]t’s difficult to pick winners,” Read acknowledges. Plus, as much as Pfizer tries to be investor-friendly… Read More
  • Business and Markets

    Where the Startup Cash Has Been Going

    If the biopharma world is awash with startup money, just where is it all going? That’s the subject of this post over at LifeSciVC, quoting a report from the BIO industry group. It covers the 2004-2013 period, so it’s missed the most recent boom year. 2013 was already the best year in the survey, and… Read More
  • Business and Markets

    Layoffs at Sanofi

    As foretold by a comment around here the other day, Sanofi seems to indeed have had the dreaded mandatory-attendance business meeting today, and I’m hearing from people who are in a position to know that layoffs have been announced internally. More details as they come out – I don’t think that the company said anything… Read More
...202122...